Strategikon Pharma
San Francisco, US · Delaware corporation · 11 known investors
Strategikon Pharma develops Clinical Maestro, a software platform for managing clinical business operations including budgeting, sourcing, contracting, and vendor management, with AI-driven cost benchmarking tools. It serves biopharmaceutical companies of all sizes and Clinical Research Organizations (CROs) involved in clinical trial outsourcing.
Founders & leadership
AC
Anca CopaescuinFounder, Chief Executive Officer
MD
Mark Di IanniCo-founder
PC
Paulo CarvalhoinExecutive
MW
Mark WeinsteininChairman of the Board of Directors
Board
RH
Rob HessBoard directorPhD biochemistry, JD, Patent Attorney, Bio-pharma, MedTech, Digital Health at SeedFolio
VL
NL
Nathanael LentzBoard director
DA
Debra ApruzzeseBoard director
CC
Chris CodeanneBoard director
Investors · 11
Band of AngelsSilicon Valley
Debiopharm Innovation FundLausanne · $1M – $5M
HearstLabNew York · $500K – $1M
Bascom VenturesreportedBoston
Decathlon Capital PartnersreportedPalo Alto
Golden Seedsreported · 2 sourcesFlushing · $250K – $2M
Osage Venture Partnersreported · 2 sourcesBala Cynwyd · $500K – $3M
Tech Coast AngelsreportedSouthern California · $5K – $50K
Also in the syndicate · 3
Life Science AngelsSaratoga Ventures, Inc.Wing Venture Capital
Funding
SEC filings, press & company announcements$2.3M disclosed across 1 of 4 rounds · 2017–2025
- Undisclosed amountSeries AApr 2021
Osage Venture Partners (lead), Band of Angels, Bascom Ventures, Golden Seeds, Life Science Angels, Saratoga Ventures, Inc., Tech Coast Angels, Wing Venture Capital
Source ↗
▶$2.3MraisedNov 2025 · 15 investors · Other TechnologyRule 506(b)
▶$2.3MraisedNov 2025 · 15 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Rob HessDirector
- Anca CopaescuExecutive Officer, Director
- Debra ApruzzeseDirector
- Chris CodeanneDirector
- Paulo CarvalhoExecutive Officer
- Vincent LepreuxDirector
- Mark WeinsteinExecutive Officer, Director
- Nathanael LentzDirector
- Offering amount
- $3M
- Amount sold
- $2.3M
- First sale
- May 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶Undisclosed amountofferedApr 2018 · Business ServicesRule 506(b)
▶Undisclosed amountofferedApr 2018 · Business Services
Rule 506(b)Officers, directors & promoters on the filing
- Anca CopaescuExecutive Officer, Director, Promoter
- Paulo CarvalhoExecutive Officer, Promoter
- Mark Di IanniExecutive Officer, Director, Promoter
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 04, 06b
▶$1MofferedNov 2017 · Business ServicesRule 506(b)
▶$1MofferedNov 2017 · Business Services
Rule 506(b)Officers, directors & promoters on the filing
- Mark Di IanniExecutive Officer, Director, Promoter
- Paulo CarvalhoExecutive Officer, Director, Promoter
- Anca CopaescuExecutive Officer, Director, Promoter
- Offering amount
- $1M
- Minimum investment
- $20K
- Proceeds to insiders
- $150K
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 04, 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- What does Strategikon Pharma do?
- Strategikon Pharma develops Clinical Maestro, a software platform for managing clinical business operations including budgeting, sourcing, contracting, and vendor management, with AI-driven cost benchmarking tools. It serves biopharmaceutical companies of all sizes and Clinical Research Organizations (CROs) involved in clinical trial outsourcing.
- Who founded Strategikon Pharma?
- Strategikon Pharma was founded by Anca Copaescu, Mark Di Ianni.
- Who are Strategikon Pharma's investors?
- Strategikon Pharma's investors include Band of Angels, Debiopharm Innovation Fund, HearstLab, Bascom Ventures, Decathlon Capital Partners, Golden Seeds, Osage Venture Partners, Tech Coast Angels.
- How much funding has Strategikon Pharma raised?
- Strategikon Pharma has disclosed $2.3M raised across 1 of its 4 known rounds.
- Where is Strategikon Pharma headquartered?
- Strategikon Pharma is headquartered in San Francisco, US.